% | $
Quotes you view appear here for quick access.

ONYX Pharmaceuticals, AŞ Message Board

  • ahhaha2 ahhaha2 Nov 3, 2012 12:46 AM Flag

    The CC, Q&A, Cannacord

    Salveen J. Richter - Canaccord Genuity, Research Division

    Just wondering with the 2,000 centers that you're targeting, what percentage are the initial high-volume and EAP centers? And how does that overlap with the 1,000 centers that have placed orders? And then also just wondering if there's any difference between use and feedback from the academic versus the community docs for Kyprolis.
    N. Anthony Coles - Chief Executive Officer, President and Director

    Helen I. Torley - Chief Commercial officer and Executive Vice President

    Yes. Salveen, I don't have the specifics on what number of -- were C-MAP patients. But let me just give you a little color of the target accounts. So of the 2,000, we were targeting about 30% were hospital based and about 70% are

    [Audio Gap]

    As we look at where the volume of prescribing is come from, it is slightly skewed to having more orders coming in from the hospital base. But we've got a good representation of adoption across both hospital and community-based accounts.